RU2603262C2 - Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1 - Google Patents

Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1 Download PDF

Info

Publication number
RU2603262C2
RU2603262C2 RU2013145467/10A RU2013145467A RU2603262C2 RU 2603262 C2 RU2603262 C2 RU 2603262C2 RU 2013145467/10 A RU2013145467/10 A RU 2013145467/10A RU 2013145467 A RU2013145467 A RU 2013145467A RU 2603262 C2 RU2603262 C2 RU 2603262C2
Authority
RU
Russia
Prior art keywords
hiv
peptide
antibodies
cells
formula
Prior art date
Application number
RU2013145467/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2013145467A (ru
Inventor
Патрис ДЕБР
Венсан ВЬЕЙАР
Original Assignee
Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль
Иннавирвакс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль, Иннавирвакс filed Critical Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль
Publication of RU2013145467A publication Critical patent/RU2013145467A/ru
Application granted granted Critical
Publication of RU2603262C2 publication Critical patent/RU2603262C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
RU2013145467/10A 2011-04-15 2012-04-13 Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1 RU2603262C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305451.4 2011-04-15
EP11305451A EP2511295A1 (en) 2011-04-15 2011-04-15 Compositions for preventing and/or treating an infection by an HIV-1 virus
PCT/IB2012/051842 WO2012140620A1 (en) 2011-04-15 2012-04-13 Compositions for preventing and/or treating an infection by an hiv-1 virus

Publications (2)

Publication Number Publication Date
RU2013145467A RU2013145467A (ru) 2015-05-20
RU2603262C2 true RU2603262C2 (ru) 2016-11-27

Family

ID=44721142

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013145467/10A RU2603262C2 (ru) 2011-04-15 2012-04-13 Композиции для предупреждения и/или лечения инфекции, вызванной вирусом вич-1

Country Status (11)

Country Link
US (3) US9181299B2 (enExample)
EP (2) EP2511295A1 (enExample)
JP (1) JP6027094B2 (enExample)
CN (1) CN103687875B (enExample)
BR (1) BR112013026150B1 (enExample)
CA (1) CA2831258C (enExample)
ES (1) ES2912099T3 (enExample)
RU (1) RU2603262C2 (enExample)
UA (1) UA112863C2 (enExample)
WO (1) WO2012140620A1 (enExample)
ZA (1) ZA201307019B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2741123C1 (ru) * 2017-04-18 2021-01-22 Инститьют Оф Пэтоджен Байолоджи, Чайниз Акэдеми Оф Медикал Сайенсиз Липопептид для эффективного ингибирования вич, его производное, фармацевтическая композиция и их применение

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2275379C2 (ru) * 2000-04-28 2006-04-27 Таймон Л.Л.С. Способы и композиции для ингибирования размножения вич-1
US20090098144A1 (en) * 2007-08-20 2009-04-16 New York University Immunogen presenting hiv gp120 v3 loop in a conformation that induces broadly neutralizing antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2002066504A2 (en) * 2001-02-16 2002-08-29 Hybrigenics Protein-protein interactions in saccharomyces cerevisiae
FR2851165A1 (fr) * 2003-02-19 2004-08-20 Aventis Pasteur Antigene derivant de l'helice c de la proteine gp41
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
CN104232679A (zh) * 2009-01-28 2014-12-24 巴斯夫植物科学有限公司 具有增强的产量相关性状的植物及其制备方法
BRPI1008721A2 (pt) * 2009-02-06 2016-03-08 Inserm Inst Nat De La Santé Et De La Rech Médicale métodos para tratamento terapêutico ou profiláctico de hiv, método profilático, composição terapêutica ou preparação, associação de vacina terapêutica, kit para implantação de método terapêutico
US20120164670A1 (en) * 2009-06-23 2012-06-28 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2275379C2 (ru) * 2000-04-28 2006-04-27 Таймон Л.Л.С. Способы и композиции для ингибирования размножения вич-1
US20090098144A1 (en) * 2007-08-20 2009-04-16 New York University Immunogen presenting hiv gp120 v3 loop in a conformation that induces broadly neutralizing antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROOT MJ, et al., HIV-1 gp41 as a target for viral entry inhibition, Curr Pharm Des, 2004, 10(15), pp.1805-1825. KRELL T., et al., HIV-1 gp41 and gp160 are hyperthermostable proteins in a mesophilic environment. Characterization of gp41 mutants, Eur J Biochem, 2004, 271(8), pp.1566-1579. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2741123C1 (ru) * 2017-04-18 2021-01-22 Инститьют Оф Пэтоджен Байолоджи, Чайниз Акэдеми Оф Медикал Сайенсиз Липопептид для эффективного ингибирования вич, его производное, фармацевтическая композиция и их применение

Also Published As

Publication number Publication date
ES2912099T3 (es) 2022-05-24
ZA201307019B (en) 2014-12-23
EP2697259A1 (en) 2014-02-19
US20160031943A1 (en) 2016-02-04
JP6027094B2 (ja) 2016-11-16
UA112863C2 (uk) 2016-11-10
EP2511295A1 (en) 2012-10-17
US20180057535A1 (en) 2018-03-01
CA2831258A1 (en) 2012-10-18
BR112013026150A2 (pt) 2016-09-06
WO2012140620A8 (en) 2013-11-07
EP2697259B1 (en) 2022-02-09
US9181299B2 (en) 2015-11-10
BR112013026150B1 (pt) 2022-08-09
US20140037666A1 (en) 2014-02-06
CN103687875A (zh) 2014-03-26
US9802983B2 (en) 2017-10-31
CN103687875B (zh) 2016-10-19
WO2012140620A1 (en) 2012-10-18
RU2013145467A (ru) 2015-05-20
US10174080B2 (en) 2019-01-08
CA2831258C (en) 2020-07-14
JP2014512367A (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
US6461612B2 (en) Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease
KR100547049B1 (ko) 바이러스 감염증 치료를 위한 조성물 및 방법
Laman et al. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain
JP2626680B2 (ja) リンパ節障害関連ウイルスに対するヒト単クローン性抗体
US5777074A (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1)
US6008044A (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC)
US10174080B2 (en) Compositions for preventing and/or treating an infection by an HIV-1 virus
EP0523056A1 (en) Neutralizing and/or adcc mediating monoclonal hiv antibody
US11267872B2 (en) Polyclonal antibodies produced using HIV-1 trimeric envelope glycoprotein subunits
CN109627297A (zh) 来自寨卡病毒e蛋白的中和表位及其应用
KR920001772B1 (ko) 포유류 중의 HIV-억제 항체 유도성 사람 면역 결핍 바이러스(HIV) env-암호화된 펩타이드
EP0418347A1 (en) Human monoclonal antibodies to human immunodeficiency virus
TERSMETTE et al. Variant-Specific Monoclonal and Group-Specific Polyclonal Human Immunodeficiency Virus Type 1 Neutralizing Antibodies Raised with Synthetic Peptides from the gpl20 Third Variable Domain